Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced or metastatic cancer~* Other available therapies have failed to cure the cancer~* The cancer that has no proven effective therapy~* The cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required)~* Able to swallow capsules~Exclusion Criteria:~* Have active cancer in the brain or spinal cord~* Have an active infection of any kind (fungal, viral, or bacterial)~* Have a cancer of the blood~* Are pregnant or breastfeeding~* Have some types of eye problems or impairments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 Dose Escalation (Type: EXPERIMENTAL): LY3009120 50 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- Cohort 2 Dose Escalation (Type: EXPERIMENTAL): LY3009120 100 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- Cohort 3 Dose Escalation (Type: EXPERIMENTAL): LY3009120 200 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- Cohort 4 Dose Escalation (Type: EXPERIMENTAL): LY3009120 400 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
- Cohort 5 Dose Escalation (Type: EXPERIMENTAL): LY3009120 500 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
- Cohort 6 Dose Escalation (Type: EXPERIMENTAL): LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
- Cohort A Dose Confirmation (Type: EXPERIMENTAL): LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- Cohort B Dose Confirmation (Type: EXPERIMENTAL): LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- Cohort C Dose Confirmation (Type: EXPERIMENTAL): LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.

Based on this trial design, predict the completion outcome and termination type (if applicable).